Table 4.
Characteristics and treatment factors of elderly patients according to modality.
| Variables | Strata | IG-IMRT n = 84 |
Brachytherapy n = 157 |
p-Value | ||
|---|---|---|---|---|---|---|
| N or Median (Range) | (%) | N or Median (Range) | (%) | |||
| Age | 77 (75–86) | 76 (75–86) | 0.0127 | |||
| T category | 1 | 23 | (27%) | 50 | (32%) | 0.0727 |
| 2 | 39 | (46%) | 85 | (54%) | ||
| 3 | 22 | (26%) | 22 | (14%) | ||
| 4 | 0 | (0%) | 0 | (0%) | ||
| Pretreatment PSA | ng/mL | 10.0 (4.3–245) | 9.4 (1.9–98.6) | 0.1644 | ||
| Gleason score | ≤6 | 23 | (27%) | 59 | (38%) | <0.0001 |
| 7 | 23 | (27%) | 70 | (45%) | ||
| ≥8 | 38 | (45%) | 28 | (18%) | ||
| NCCN risk classification | Low | 10 | (12%) | 27 | (17%) | <0.0001 |
| Intermediate | 22 | (26%) | 86 | (55%) | ||
| High | 52 | (62%) | 44 | (28%) | ||
| Treatment modality | HDR-BT | 87 | (61%) | NA | ||
| LDR-BT | 70 | (39%) | ||||
| Hormonal therapy | Yes | 64 | (76%) | 95 | (61%) | 0.0211 |
| No | 20 | (24%) | 62 | (39%) | ||
| Follow-up | Months | 73.4 (24–90) | 77.3 (14.5–161) | 0.0312 | ||
Bold values indicate statistical significance. NA = not available; PSA = prostate-specific antigen; NCCN = National Comprehensive Cancer Network; HDR-BT = high-dose-rate brachytherapy; LDR-BT = low-dose-rate brachytherapy; IG-IMRT = image-guided intensity-modulated radiotherapy.